# Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

> **NCT04884399** · PHASE1 · COMPLETED · sponsor: **Shanghai Biomabs Pharmaceutical Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** CMAB818
- **DRUG:** Lucentis®

## Key facts

- **NCT ID:** NCT04884399
- **Lead sponsor:** Shanghai Biomabs Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-03
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884399, "Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04884399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*